PADI4 and rheumatoid arthritis: A subgroup of patients with RA possesses cross-reactive antibodies towards both PAD3 and PAD4, named anti-PAD3/4XR antibodies, that may predict ILD occurrence, especially in never-smoking patients (85), an association not found for anti-PAD3 or anti-PAD4 antibodies alone.